PURPOSE: The National Surgical Adjuvant Breast and Bowel Project (NSABP) C-07 trial demonstrated that the addition of oxaliplatin to fluorouracil plus leucovorin (FULV) improved disease-free survival (DFS) in patients with stage II or III colon cancer. This analysis is the first publication of overall survival (OS) for the NSABP C-07 study. We updated DFS and examined both end points in clinically relevant patient subsets. PATIENTS AND METHODS: Other studies have identified patients age 70 or older and those with stage II disease as patient subsets in whichoxaliplatin may not be effective. We investigated toxicity as a driver of divergent outcomes in these subsets. RESULTS: In all, 2,409 eligible patients with follow-up were randomly assigned to either FULV (FU 500 mg/m(2) by intravenous [IV] bolus weekly for 6 weeks; leucovorin 500 mg/m(2) IV weekly for 6 weeks of each 8-week cycle for three cycles) or FLOX (FULV plus oxaliplatin 85 mg/m(2) IV on days 1, 15, and 29 of each cycle). With 8 years median follow-up, OS was similar between treatment groups (hazard ratio [HR], 0.88; 95% CI, 0.75 to 1.02; P = .08). FLOX remained superior for DFS (HR, 0.82; 95% CI, 0.72 to 0.93; P = .002). The effect of oxaliplatin on OS did not differ by stage of disease (interaction P = .38 for OS; interaction P = 0.37 for DFS) but did vary by age for OS (younger than age 70 v 70+ interaction P = .039). There was a similar trend for DFS (interaction P = .073). Oxaliplatin significantly improved OS in patients younger than age 70 (HR, 0.80; 95% CI, 0.68 to 0.95; P = .013), but no positive effect was evident in older patients. CONCLUSION: Overall, the addition of oxaliplatin to FULV has not been proven to extend OS in this trial, but the DFS effect remained strong. Unplanned subset analyses suggest a significant OS effect of oxaliplatin in patients younger than age 70.
RCT Entities:
PURPOSE: The National Surgical Adjuvant Breast and Bowel Project (NSABP) C-07 trial demonstrated that the addition of oxaliplatin to fluorouracil plus leucovorin (FULV) improved disease-free survival (DFS) in patients with stage II or III colon cancer. This analysis is the first publication of overall survival (OS) for the NSABP C-07 study. We updated DFS and examined both end points in clinically relevant patient subsets. PATIENTS AND METHODS: Other studies have identified patients age 70 or older and those with stage II disease as patient subsets in which oxaliplatin may not be effective. We investigated toxicity as a driver of divergent outcomes in these subsets. RESULTS: In all, 2,409 eligible patients with follow-up were randomly assigned to either FULV (FU 500 mg/m(2) by intravenous [IV] bolus weekly for 6 weeks; leucovorin 500 mg/m(2) IV weekly for 6 weeks of each 8-week cycle for three cycles) or FLOX (FULV plus oxaliplatin 85 mg/m(2) IV on days 1, 15, and 29 of each cycle). With 8 years median follow-up, OS was similar between treatment groups (hazard ratio [HR], 0.88; 95% CI, 0.75 to 1.02; P = .08). FLOX remained superior for DFS (HR, 0.82; 95% CI, 0.72 to 0.93; P = .002). The effect of oxaliplatin on OS did not differ by stage of disease (interaction P = .38 for OS; interaction P = 0.37 for DFS) but did vary by age for OS (younger than age 70 v 70+ interaction P = .039). There was a similar trend for DFS (interaction P = .073). Oxaliplatin significantly improved OS in patients younger than age 70 (HR, 0.80; 95% CI, 0.68 to 0.95; P = .013), but no positive effect was evident in older patients. CONCLUSION: Overall, the addition of oxaliplatin to FULV has not been proven to extend OS in this trial, but the DFS effect remained strong. Unplanned subset analyses suggest a significant OS effect of oxaliplatin in patients younger than age 70.
Authors: D J Sargent; R M Goldberg; S D Jacobson; J S Macdonald; R Labianca; D G Haller; L E Shepherd; J F Seitz; G Francini Journal: N Engl J Med Date: 2001-10-11 Impact factor: 91.245
Authors: J Philip Kuebler; H Samuel Wieand; Michael J O'Connell; Roy E Smith; Linda H Colangelo; Greg Yothers; Nicholas J Petrelli; Michael P Findlay; Thomas E Seay; James N Atkins; John L Zapas; J Wendall Goodwin; Louis Fehrenbacher; Ramesh K Ramanathan; Barbara A Conley; Patrick J Flynn; Gamini Soori; Lauren K Colman; Edward A Levine; Keith S Lanier; Norman Wolmark Journal: J Clin Oncol Date: 2007-04-30 Impact factor: 44.544
Authors: J Philip Kuebler; Linda Colangelo; Michael J O'Connell; Roy E Smith; Greg Yothers; Mirsada Begovic; Bridget Robinson; Thomas E Seay; Norman Wolmark Journal: Cancer Date: 2007-11-01 Impact factor: 6.860
Authors: Hanna K Sanoff; William R Carpenter; Til Stürmer; Richard M Goldberg; Christopher F Martin; Jason P Fine; Nadine Jackson McCleary; Jeffrey A Meyerhardt; Joyce Niland; Katherine L Kahn; Maria J Schymura; Deborah Schrag Journal: J Clin Oncol Date: 2012-06-04 Impact factor: 44.544
Authors: S Ahmed; O Bathe; S Berry; D Buie; J Davies; C Doll; S Dowden; S Gill; V Gordon; P Hebbard; E Jones; H Kennecke; S Koski; M Krahn; D Le; H Lim; C Lund; Y Luo; A Mcffadden; J Mcghie; K Mulder; J Park; F Rashidi; A Sami; K T Tan; R Wong Journal: Curr Oncol Date: 2015-04 Impact factor: 3.677
Authors: Paul L Feingold; Nicholas D Klemen; Mei Li M Kwong; Barry Hashimoto; Udo Rudloff Journal: Int J Hyperthermia Date: 2017-12-07 Impact factor: 3.914
Authors: Felipe Quezada-Diaz; Rosa M Jimenez-Rodriguez; Emmanouil P Pappou; J Joshua Smith; Sujata Patil; Iris Wei; Jose G Guillem; Philip B Paty; Garrett M Nash; Martin R Weiser; Julio Garcia-Aguilar Journal: J Gastrointest Surg Date: 2018-10-22 Impact factor: 3.452
Authors: Nadine J McCleary; Kaori Sato; Reiko Nishihara; Kentaro Inamura; Teppei Morikawa; Xuehong Zhang; Kana Wu; Mai Yamauchi; Sun A Kim; Yasutaka Sukawa; Kosuke Mima; Zhi Rong Qian; Charles S Fuchs; Shuji Ogino; Jeffrey A Meyerhardt Journal: Clin Cancer Res Date: 2015-10-21 Impact factor: 12.531